

Available online on 15.07.2016 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

An International Peer Reviewed Journal

Open access to Pharmaceutical and Medical research

© 2016, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

RESEARCH ARTICLE

FORMULATION OF AN INSITU FORMING INJECTABLE SUSTAINED RELEASE SPONGE OF GRANISETRON HYDROCHLORIDE

Reshma Mirajkar*, Renuka Jagtap, Ashwini Madgulkar

Department of Pharmaceutics, AISSMS College of Pharmacy, Kennedy Road, Pune 411001, Maharashtra, INDIA

Received 02 June 2016; Review Completed 30 June 2016; Accepted 30 June 2016, Available online 15 July 2016

ABSTRACT

The overall aim of this work was to develop sustained release parenteral drug delivery system involving formation of an *insitu* sponge of anti-emetic drug typically co-administered in chemotherapy induced nausea and vomiting. The study involved formulation of the drug Granisetron Hydrochloride in a sponge forming gelatin matrix as a dry powder for reconstitution into a suspension to be injected into the body forming a sponge *insitu* intended to release the drug over a period of 5 days. The formulation was prepared by the method cryogelation and optimised using gelatin 5% as a sponge forming polymer, crosslinking agent glutaraldehyde 0.3% , sustained release retardant Hydroxypropylmethyl cellulose K100M 1% (HPMC K100M) and suspending agent sodium carboxymethylcellulose 1% (NaCMC) to form a solution intended to be administered subcutaneously. The formulation was evaluated for all prerequisites of parenteral and other parameters of gelatin matrix like swelling index, surface scanning microscopy for injectable suspension, sedimentation study, particle size, zeta measurement, *in-vitro* drug release, and stability studies. The formulation was found to be sterile, isotonic, having swelling index 88% and SEM 100-120 µm, particle size 0.765µm. with zeta potential -14.2 mV, swelling time was 10 min. The *in vitro* drug release was found to be over 93.20% in Simulated Body fluid pH 7.4 at 37°C over a prolonged period of 5 days. The formulation was physically and chemically stable at accelerated conditions for period of 1 month.

Keywords: anti-emetic, gelatin matrix, cryogelation, injectable suspension

INTRODUCTION:

The Parenteral route is the most effective and common form of drug delivery system. It is used for which the bio-availability is limited by high first pass metabolism effect of other physicochemical limitation and for drugs with a narrow therapeutic index. Parenteral drug delivery has different technologies that can reduce the total number of injection throughout the drug therapy period. Sustained parenteral drug delivery began to emerge as a clearly designed sub-area of pharmaceutics in the middle of the twentieth century. Development of new sustained release injectable formulation has received considerable attention due to many advantages of these systems such as localized and site-specific action, prolonged delivery period, decreased drug dosages, reduction of side effects and improved patient comfort and compliance over the conventional parenteral delivery.^{1,2}

Sustained release injectable formulations are basically designed as microparticles (microcapsules or microspheres), sponges, implants or gel systems. Microparticles are produced by complicated methods. They also suffer from several limitations such as low drug loadings, difficulty in particle size control due to aggregation and difficulty in their reconstitution to

initial size. Efficiency of loading methods for active ingredients is limited and a high loading capacity is usually unattainable. A major limitation of implants is the requirement of surgery to remove the system which adds to their costs and risks. Due to these limitations and drawbacks many researchers have proposed the use of injectable sponge formulations as substitutes.³

Injectable sponge drug delivery system can entrap wide range of drugs and then release them into body over time. It is a unique technology for the novel release of injectable agents and consists of nano or micro porous beads loaded with active agent. After the creation of micro beds or matrix, it gets compressed following the compression the sponge gets filled with active agent or medicine and injected into body. Following the injection, the sponge will expand to the original size and shape and start releasing drugs. Sponges or scaffolds have been developed using various techniques such as fiber bonding, gas foaming, microemulsion formation, phase separation, freeze-drying, and porogen leaching. More recently, gelation at sub-zero temperatures, known as cryogelation, has been used to create sponge with large interconnected pores. During cryogelation, the reactants are restricted to the unfrozen/semifrozen phases and form a cross-linked network upon polymerization, while the ice

crystals nucleated from the aqueous phase during freezing function as porogens. The melting of these ice crystals at temperature above the freezing temperature gives rise to interconnected macroporous networks. Injectable sponge drug delivery system which involves use of natural injectable polymers like chitosan, gelatin, sodium alginate, collagen etc. which act as a depot and release the drug in a timely fashion.^{4,5,6}

Gelatin is a natural polymer which is biodegradable, nontoxic in nature. Due to its easy process ability and gelation properties, gelatin has been manufactured in a range of shapes including sponges, injectable hydrogels and gelatin microspheres etc. Gelatin sponges or matrices have been utilized for many regional drug delivery systems among the other forms of gelatin. Absorbable gelatin sponge (AGS) was introduced by Correl and Weisman as absorbable hemostatic agent in 1945.⁷

Granisetron hydrochloride (GH) is antiemetic drug, effective both intravenously and orally, acts by antagonizing 5HT₃ receptor in the chemoreceptor trigger zone and probably in upper gastrointestinal tract. GH is used in management of nausea and vomiting induced by cytotoxic chemotherapy, radiotherapy and for the prevention of post operating nausea and vomiting. GH has 60% oral bioavailability due to hepatic first pass metabolism by 7 hydroxylation. Therefore it would be desirable to develop a sustained drug delivery system without this limitation of frequent administration. Recommended dose of GH is 2 mg/day twice a day before 30 min of chemotherapy induced nausea and vomiting for 5-7 days.⁹

The present work was focused on formulation of an injectable sponge of Granisetron Hydrochloride in a gelatin matrix system intended for a 5-day sustained release to be administered in patients suffering from chemotherapy induced nausea and vomiting.

MATERIALS

Granisetron Hydrochloride was obtained as a generous gift from Wockhardt Research Center (Aurangabad, India). Gelatin was purchased from Lobachemie (Mumbai, India). Glutaraldehyde was purchased from LobaChemie (Mumbai, India). HPMC K100M was purchased from Otto Chemie, Sodium CMC was purchased from LobaChemie (Mumbai, India). All other chemicals and reagents were of the analytical grade.

METHODS

Part A] Preparation and Evaluation of Gelatin matrix

Preparation

Gelatin was soaked in 100ml of water for 30 m to get solution at the varying concentration of 1-6% w/v of gelatin. The drug granisetron HCL (10mg) was added followed by addition of crosslinker glutaraldehyde (0.1-05 %) and then added sustained release polymer HPMC K100M (0.25-2%). This solution was then stirred vigorously for 10 m at 1000 rpm using overhead

stirrer to form a firm foam. This foam was separated and spread on petri plates and further subjected to process of cryogelation. The process involved drying of gelatin matrix in deep freezer at -10 to -12 °C temperature for 24 h till it formed a dry porous matrix mass. This dry gelatin matrix mass was sifted through 16 # to get fine brown coloured powder in aseptic condition. Optimised concentration of suspending agent sodium CMC (1%) was added, the powder was aseptically filled in previously sterilised amber coloured vials 2ml and then were subjected to sterilization by hot air oven at 140°C temperature for 2 h.^{4,7}

Optimization study

A two factor, three levels full factorial design was employed for the optimization of Granisetron HCL gelatin matrix using Design-expert software[®] 9.0 (Stat-Ease, Inc., USA). The experimental design was applied to study the effect of independent factors such as gelatin concentration and glutaraldehyde concentration on dependent variables i.e. swelling index and pore size

Table 1: Formulation combination as per the 3² full factorial designs for Granisetron gelatin matrix.

Formulatio Code	Gelatin % w/v	GLU (% v/v)
F1	6	0.1
F2	5	0.1
F3	4	0.5
F4	4	0.3
F5	4	0.1
F6	5	0.3
F7	6	0.3
F8	6	0.5
F9	5	0.5

Evaluation of Gelatin matrix

Appearance

The appearance and physical characteristics of the gelatin matrix were checked by visual observation and using optical microscope microscopy.

Drug Excipient Compatibility study

The FTIR spectrum of pure drug and physical mixture in 1:1 ratio were recorded on spectrophotometer for interaction between them by using KBr pellet method.

Swelling Index

Swelling index was determined by soaking pre-weighed pieces (1 x 1 cm) of gelatin matrices in double distilled water. Soaked matrices were removed with blunt forceps and blotted to remove excess liquid from the medium at predetermined time (5, 10, 15 m) and their weight was determined by using digital weighing balance and % swelling index was calculated by the following equation.^{4,5}

$$\% S = \frac{W_2 - W_1}{W_1} \times 100$$

Where, S is the percentage water adsorption of gelatin matrices at equilibrium.

W1 is the initial weight of the gelatin matrix.

W2 is the after immersion weight of the gelatin matrix.

Surface scanning study

Morphological analysis was carried out by a scanning electron microscope (SEM) JEOL model JSM-6390LV. Surface morphology of gelatin matrix can be observed by using SEM. Gelatin matrix was mounted on aluminium pin stubs using conductive self-adhesive carbon label.⁷

Part B] Preparation and Characterization of Injectable suspension

Preparation

Injectable suspension was prepared by reconstitution of formulation. Dry gelatin matrix powder was reconstituted in 2ml of sterile water for injection (SWFI) at the time of administration to form an injectable suspension.

Evaluation of Injectable suspension

Appearance and pH

The appearance of formulation was checked by visual observation and pH of injectable suspension was measured using pH meter which was previously calibrated using standard buffers of pH 4 & pH 7.

Syringeability

Syringeability of the formulation was assured using 21 to 26 G needles. It was important to assure syringeability of formulation prior to animal study. All prepared formulations were withdrawn into identical 5 ml plastic syringes placed with 21 to 26 gauge needles to a constant volume (1 ml). The solutions which were easily passed from a particular syringe were termed as pass and the ones which were difficult to pass were termed as fail.^{8,10}

Sedimentation Volume

In sedimentation study, the suspension was transferred to a stoppered measuring cylinder and was stored at room temperature for 24 h. The volume of sediment formed was noted at regular interval of time (1, 3, 5, 8 h).^{8,10}

$$\text{Sedimentation volume} = \frac{\text{final volume (Vu)}}{\text{Original volume (VO)}}$$

Swelling Time

Swelling time was observed visually for gelatin matrix. Dry gelatin matrix powder was added in 2ml Simulated body fluid (PH 7.2) Time required to swell was determined.

Particle Size and Zeta Potential Measurements

Formulation was suspended in water and sonicated to form a smooth and uniform dispersion. The particle size and zeta potential of the formulation was obtained

using a Malvern particle size analyzer (Mastersizer-2000, UK).^{4,8}

Drug content estimation

0.25 ml of the test formulation was diluted with excess of methanol and evaporated to dryness. The residue was diluted up to 100 ml with mobile phase to get a stock solution of 100µg/ml. From this stock solution, a solution of 40 µg/ml was prepared and analysed by HPLC.¹⁴

Sterility Testing

Sterility testing was carried out as per the IP 2014. The formulation was incubated for not less than 14 days at 30°-35°C in the alternate fluid thioglycolate medium to find the growth of bacteria & at 20°-25°C in Soya bean casein digest medium to find the growth of fungi in formulation. The test was performed using positive and negative controls. The bacterial strain used for positive control was *Clostridium sporogenes* whereas the fungal strain was *Candida albicans*¹⁵

In-vitro Drug Release Studies

In vitro release studies of Granisetron HCL from Injectable gelatin suspension system was performed at 37 °C using membraneless dissolution model. The dissolution medium was simulated body fluid pH 7.2. 1 ml of dissolution medium was withdrawn at specific time intervals and replenished with fresh medium to maintain sink conditions. Orbital shaking Incubator was used to maintain the temperature at 37 °C and agitated for 30 rpm. Aliquots withdrawn were suitably diluted and analyzed using UV spectrophotometer at 302nm.¹¹

Accelerated Stability study

Stability studies were carried out on optimized formulation according to International Conference on Harmonization (ICH) guidelines. Formulations were filled in vials and subjected to room temperature i.e. at 25°C ± 2°C/60% ± 5% RH and 40°C ± 2°C/75% RH ± 5% RH for 1 month. Samples were analysed for appearance, pH and in vitro drug release.¹⁶

RESULTS AND DISCUSSIONS

Optimization study

The design of experiment (DOE) is an approach in which process variables are first screened and then optimized to determine best settings for the variables. Full factorial design is a quadratic design which requires 3 levels for each factor.

From the all batches F6 batch was selected that attained the desired swelling index i.e. 88 % and pore size was found to be 11.9 µm and was further evaluated. The results of the each experiments performed as per the software are given in Table 2. Empirical relationships between the response and the independent variables have been expressed by the following quadratic model.¹³

Table 2: Formulation combination as per the 3² full factorial design with response

Formulation Code	Swelling Index (%)	Pore size (µm)
F1	68	5.7
F2	78	8.7
F3	60	5.6
F4	58	3.2
F5	50	4.3
F6	88	11.9
F7	71	2.5
F8	73	4.7
F9	75	9.7

Response Surface plots




Figure 1: Response surface of swelling index

$$\text{Swelling Index} = +84.33 + 8.33 * A + 1.00 * B + 0.25 * AB - 18.00 * A^2$$

Where, A is concentration of gelatin and B is Concentration of glutaraldehyde.

Swelling index is the capacity of swelling in body. It is important parameter in injectable sponge preparation and it depends on polymer concentration i.e. gelatin and crosslinking agent i.e. glutaraldehyde.

As shown in figure1 upon increase in concentration of gelatin and glutaraldehyde there is increase in swelling index. It was found that with increase in concentration of gelatin from 4% to 5% and of glutaraldehyde 0.1 to 0.3 % swelling index increases but at concentration

beyond 5 % to 6% of gelatin and 0.3% of glutaraldehyde highly viscous solutions are formed which is difficult to stir and formulate into foam.




Figure 2: Response surface of pore size

$$\text{Pore size} = +10.99 + 0.57 * A + 2.05 * B + 1.13 * AB + 2.23 * A^2 - 2.78 * B^2$$

Where, A is concentration of gelatin and B is Concentration of glutaraldehyde.

Glutaraldehyde is a crosslinker which mainly contributes to form a porous matrix of gelatin once it swells in fluid. It was found (figure 2) that with increase in concentration of gelatin from 4% to 5% and of glutaraldehyde from 0.1 to 0.3 %, pore size increases but at concentration beyond 5 % to 6% of gelatin and of 0.3% of glutaraldehyde highly viscous solutions is formed which is difficult to stir and formulate into a foam therefore there was also a decrease in pore size. Thus as per optimization study 0.3% concentration of glutaraldehyde gives higher pore size.

Contribution of concentration of polymer and crosslinking agent has effect on both the parameters i.e. swelling index and pore size. As the matrix swells in the media it forms porous sponge. The pore size of the sponge entraps the drug and slowly releases the drug. Thus 5% of gelatin concentration and 0.3% Concentration of glutaraldehyde was selected for further study that gave maximum swelling and pore size of the sponge.

Table 3: Desirability function of optimized formulation

Formulation Code	Gelatin Concentration (% w/v)	Glutaraldehyde Concentration. (% v/v)	Desirability
F 6	5	0.3	0.9762

The release is prolonged over the predetermined time period depending upon the concentration of the release retardant HPMC K100M added.

The quality of the fitted model was expressed by the coefficient of determination R², and its statistical significance was checked by an F-test (analysis of variance) at the 5% significance level. The statistical

significance of the regression coefficients was determined by using the t-test (only significant coefficients with p-value < 0.05 are included). The

optimum processing conditions were obtained by using graphical and numerical analysis based on the criteria of the desirability function and the response surface.

Table 4: ANOVA test result

SOURCE	ABSORBANCE		
	F-value	P-value	R-square
Quadratic model	11.61	0.0001	0.9508

PART A] Evaluation of Gelatin Matrix

Appearance

All the formulations were brown colour, brittle matrix powder in appearance. Dry heat sterilization had no effect on physical and chemical properties of the formulation.

Drug Excipient Compatibility study




Figure 3: FT-IR Spectra of A) Drug B) Drug + Gelatin C) Drug + HPMCK100M and D) formulation of Granisetron HCL

The FTIR spectrum of pure drug and physical mixture in 1:1 ratio were recorded on spectrophotometer and it shows no any significant change in functional group peak i.e. there was no major interaction between drug and excipients. The characteristic IR absorption peaks of Granisetron HCL and other excipients were at 720-780cm⁻¹(C-H stretch), 2410-2550cm⁻¹(C-H=O), 1650-1580cm⁻¹(N-H bend), 3400-3200cm⁻¹(N-H stretch) present as shown in (figure 3). FTIR spectra of the formulation with polymers showed all the Granisetron HCL characteristics absorption bands suggesting there is no chemical interactions between the drug and polymers used in the formulation.¹⁴

Swelling Index

The prepared matrices were subjected to swelling Index which ranged from 50 % to 88 %. Swelling index of optimized F6 batch was found to be 88%. It represents the capacity of swelling of matrix in blood. In body gelatin matrix absorbs blood or body fluid

and it opens the pores of matrix to gives sustained release of drug over 5 days period. As shown in fig 5% gelatin concentration has higher swelling property and also gives higher sustained to release of drug.



Figure 4: Effect of concentration of polymer on swelling index

Scanning electron Microscopy

Scanning electron Microscopy is used to study the microscopic aspects of the formulation. The Gelatin matrix appeared as a very porous and rough structure. The pore size was in the range of 100-120 μm . Morphology of gelatin sponge is shown in figure 5.




Figure 5: Scanning electron Microscopy of gelatin matrix

B] Evaluation of Injectable suspension-

Appearance and pH

All the formulations were dispersed suspension system. The pH of the all the formulations was found to be between 6.5-7. The pH values were found to be in the range tolerated by the subcutaneous tissue. Moreover, the drug was found to be most stable in this pH range.

Syringeability

The formulation easily passed through the needle gauge 21. This needle size is suitable for subcutaneous injection.

Table 5: Syringeability of optimized formulation

Needle gauge no.	Result
21	Pass
22	Fail
24	Fail
26	Fail

Sedimentation study

The sedimentation volume can have values ranging from less than 1. The sedimentation volume was found to be constant 0.075 for a period of 15 min. The ultimate height of the solid phase depends on the concentration of solid and the particle size.

Table 6: Sedimentation study of gelatin matrix powder

TIME	Sedimentation volume
5 min	0.050
10 min.	0.075
15 min	0.075

Swelling time

Swelling time of gelatin matrix was 10 m. It is time required to swell after injecting the reconstituted powder in sterile water for injection and thus formation of sponge *in-situ*

Particle Size and Zeta Potential Measurements

Particle size of gelatin suspension was found to be 0.7654 μm (765.4 d.nm) and Pdl was 0.665. gelatin suspension has good particle size that indicates formulation will easily administered in body and easily passed through blood vessels.

Zeta potential is a measure of surface charge. Zeta potential of formulation was -14.2 Mv that means gelatin suspension has good physical stability. Zeta Potential determinations can be great value in the development of suspensions, particularly if the controlled flocculation approach is used to formulate.




Figure 6: Particle Size of gelatin suspension.




Figure 7: Zeta potential of gelatin suspension.

Drug content estimation

The percentage drug content in the formulation was calculated and found to be 95.54 % indicating insignificant loss of drug during the formulation.

Sterility testing

No turbidity was observed in test samples after 14 days. The formulation was found to be free from bacteria and fungi. Hence, it passes the test for sterility as per I.P. The sterility of the formulation may be attributed to aseptic process of preparation and filling the amber colour vials and dry heat sterilization at 140°C temperature for 2 h.

Table 7: Observations for bacterial growth

Sample	Observation
Positive control	Growth
Negative control	No growth
Test sample	No growth

Table 8: Observations for fungal growth

Sample	Observation
Positive control	Growth
Negative control	No growth
Test sample	No growth

In-vitro Drug Release Studies

In vitro drug release study serve as a comparative tool in formulation and development. Drug release from gelatin matrix into release medium was regulated by dissolution or diffusion of drug, depending upon experimental conditions. In vitro drug release of gelatin matrix formulation was regulated by diffusion mechanism. As the concentration of HPMC K100M increases drug release was retarded. The release on subsequent days was at par with the expected values. About 93.20 % of drug release was observed on the last day which indicated sustenance of the release for 5 days

Table 9: In-vitro Drug Release of formulation

Time(days)	Cumulative % Drug release
1	18.50
2	38.35
3	57.20
4	76.23
5	93.20




Figure 8: In vitro release profile for optimized formulation

Table 10: Model for release kinetics

Formulation F6	Zero order	First order	Korsmeyer-Peppas order	Higuchi order
R ²	0.972	0.893	0.984	0.975

It is evident from above data (Table 10) that Korsmeyer peppas model was the best fit model for optimized batch. It indicates that the optimized formulation followed non-Fickian diffusion mechanism for drug release.

Accelerated stability study

Stability studies indicates that formulation F6 was physically and chemically stable at ambient

temperature i.e at 25°C ± 2°C/60% RH ± 5% RH and at accelerated conditions 40°C ± 2°C/75% RH ± 5% RH for a period of 1 month. From stability studies it was observed that the formulation of Granisetron HCL was stable at selected storage conditions in amber coloured vials. It shows no change in appearance, colour, pH, with negligible decrease in vitro drug release.

Table 10: Stability studies results after 1 month

Formulation code	Storage condition	Appearance, colour, pH		In vitro drug Release (%) after 1 month
		Before Reconstitution of gelatin matrix	After Reconstitution of gelatin matrix	
F6	Room temperature(25°C ± 2°C/60% RH ± 5%)	Brown powder	Dispersed suspension, 6.4	92.97
	Accelerated temperature(40°C ± 2°C/75% RH ± 5% RH)	Brown powder, 6.3	Dispersed suspension, 6.2	90.34




Figure 9: *In vitro* release after 1 month

CONCLUSION

The present work was based on the need to reduce the frequency of administration of Granisetron Hydrochloride. It can be concluded that sustained-release parenteral formulations are helpful in increasing the efficiency of the dose as well as improving the patient's compliance. Sustained release injectable gelatin sponge formulation Granisetron Hydrochloride would be advantageous over the prevailing tablets and injections, that require administration every for 12

for 5 days regimen. Injectable gelatin sponge formulations can be anticipated as a promising alternative to conventional oral and parenteral dosage forms. Thus makes easing the practice of medication with an objective to save the valuable life of human being.

ACKNOWLEDGEMENT

The authors are a grateful to AISSMS College of Pharmacy, Pune, India.

REFERENCES

- Wright J, Hoffman A, Historical overview of long acting injections and implants, *Springer*, 2012; 11
- Chenite A, Chaput C. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. *Biomaterials*2000; 21: 2155–2161.
- Malik K, Singh I, Nagapal M, Arora S. Atrigel A Potential parenteral controlled drug delivery system. *Pelagia Research Library, Der Pharmacia sinica*. 2010; 1(1):74-81
- Princely S., Design and evaluation of controlled release gentamycin incorporated gelatine alginate matrices for wound management , *Scholars Research Library*, 2015, 7 (1):145-153
- Perry. C, Kusek. K, Injectable Sponge delivers Drug, *Cells and Structure*, Nov 13,2013
- David J; Injectable Preformed Scaffolds with Shape Memory Property :1- 6
- Wei S., Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors, *International Journal Of Nanomedicine*;1499
- Patel R., a Review on Parenteral Suspension , *International Journal of Current Pharmaceutical Research* ;Vol 2, Issue 3, 2010
- Product monograph, Granisetron hydrochloride injection, Omega Laboratories Ltd, 2013; 1-23.
- Alam A., Formulation and Evaluation of Pharmaceutically Equivalent Parenteral Depot Suspension of Methyl Prednisolone Acetate, *Indian J Pharm Sci.*; 2009 Jan-Feb; 71(1): 30–34
- Tiwari S, Saihboomi A. Extended release improving formulation of HPMC matrices. *Advancing process solutions pharmaceutical technology Europe*. Peer Review. An Advan star publication.2008; 1-8.
- Ranga S, A review on design of experiments (DOE) Review article. *Int J of pharm and chemsci*.2014; 3(1):26-224.
- Kalsi PS: Spectroscopy of organic compounds. New age international publishers. Fifth edition: p.60-159.
- Bhalerao AV, Analysis of Stability of Granisetron Hydrochloride in Nasal Formulations by Stability-Indicating RP-HPLC Method, *Research Journal of Pharmaceutical, Biological and Chemical Sciences*; Volume 4 Issue 4,Oct – Dec, 2013 ;653-662
- Indian Pharmacopoeia 2014.Government of India ministry of health and family welfare. Published by The Indian pharmacopoeial commission. Ghaziabad, vol-I, 7thedition, 59-66.
- International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Stability testing of new drug substances and products Q1A(R2).4th version.200

*Corresponding Author

Reshma Mirajkar

Department of Pharmaceutics, AISSMS College of Pharmacy, Near RTO, Kennedy Road, Pune. 411001, Maharashtra, India **Email:** reshamirajkar@gmail.com, **Phone. No.** – 9422760018

How to cite this article:

Mirajkar R, Jagtap R, Madgulkar A, **Formulation of an in-situ forming injectable sustained release sponge of granisetron hydrochloride**, *Journal of Drug Delivery & Therapeutics*. 2016; 6(4):55-62